Ambu ASWBO:AMBU +0.28%63 5-Year RORE % is 14.73 as of Mar. 2026. GuruFocus rates WBO:AMBU with a GF Score™ of 63/100 and a GF Value™ of €17.17 (Significantly Undervalued). Among 706 Medical Devices & Instruments companies, Ambu AS ranks better than 75.78% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Ambu AS's 5-Year RORE % for the quarter that ended in Mar. 2026 was 14.73%.
The industry rank for Ambu AS's 5-Year RORE % or its related term are showing as below:
WBO:AMBU's 5-Year RORE % is ranked better than 75.78% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: -5.13
vs WBO:AMBU: 14.73
Ambu AS (WBO:AMBU) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Ambu AS 5-Year RORE % Related Terms
Ambu AS 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Ambu AS's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:AMBU vs ABT, SYK, MDT: 5-Year RORE % Comparison
For the Medical Devices subindustry, Ambu AS's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambu AS 5-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ambu AS's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Ambu AS's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Ambu AS (WBO:AMBU) has a 5-Year RORE % of 14.73 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Ambu AS and its competitors. According to the industry distribution chart, Ambu AS ranks #171 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 24.2%.
Is Ambu AS's 5-Year RORE % too high?
Ambu AS's current 5-Year RORE % is 14.73. Based on the distribution chart, Ambu AS ranks #171 out of 706 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ambu AS has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ambu AS's 5-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ambu AS ranks #171 out of 706 companies for 5-Year RORE %. This places Ambu AS in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Ambu AS and its competitors. Ambu AS's current 5-Year RORE % is 14.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambu AS stock overvalued right now?
Based on GuruFocus' analysis, Ambu AS (WBO:AMBU) is currently considered Significantly Undervalued. The stock's GF Value™ is €17.17, compared to a current price of €8.90 — trading 48.2% below its estimated fair value. The current 5-Year RORE % is 14.73. Ambu AS's overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Ambu AS (WBO:AMBU), the current 5-Year RORE % is 14.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambu AS (WBO:AMBU) Overvalued in 2026?
Based on GuruFocus' analysis, Ambu AS stock appears to be undervalued.
The current stock price of €8.90 is trading 48.2% below its estimated GF Value™ of €17.17.
GuruFocus considers Ambu AS to be Significantly Undervalued.
Key valuation signals for WBO:AMBU:
5-Year RORE %: 14.73
GF Value™: €17.17 vs. price of €8.90 (48.2% below fair value)
No single metric tells the full story. See the WBO:AMBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambu AS provides medical technology solutions. The company's business consists of research and development of new solutions, which are then manufactured, marketed, and sold. It operates in two verticals: Endoscopy Solutions and Anesthesia & Patient Monitoring, with the majority of revenue being generated from the Endoscopy Solutions business. Geographical segments include North America, Europe, and the Rest of the World.
63GF Score
Get the complete analysis for WBO:AMBU
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:AMBU has been successfully added to your 
